# Cystic lesions and their role in pancreatic cancer risk stratification

**Authors:** Rebecca Lyons, Stephen G. Maher, Joanne Lysaght

PMC · DOI: 10.1016/j.tranon.2026.102704 · Translational Oncology · 2026-02-21

## TL;DR

This paper reviews how pancreatic cystic lesions can be used to better identify patients at risk for pancreatic cancer by incorporating immunobiological factors into current guidelines.

## Contribution

The paper proposes integrating immunobiological factors into risk-stratification guidelines for pancreatic cystic lesions to improve early detection of pancreatic cancer.

## Key findings

- Pancreatic cystic lesions can undergo malignant transformation and are considered precursors to pancreatic cancer.
- Current risk-stratification guidelines for pancreatic cystic lesions are controversial and lack integration of immunobiological factors.
- Incorporating immunobiological components may improve identification of high-risk patients for pancreatic cancer.

## Abstract

•PC is difficult to detect and to diagnose and is frequently diagnosed at advanced stages where treatment options and efficacy are limited.•A number of risk-factors are associated with the biological establishment of pancreatic cancer including pre-malignant pancreatic cystic lesions.•Certain pancreatic cystic lesions possess the ability to undergo malignant transformation and are regarded as precursor lesions for pancreatic cancer.•Risk-stratification guidelines for the diagnosis and management of pancreatic cystic lesions remains highly contended within the field.•Incorporation of an immunobiological component to current risk-stratification guidelines of pancreatic cystic lesions may permit more accurate identification of at-risk patients for pancreatic cancer.

PC is difficult to detect and to diagnose and is frequently diagnosed at advanced stages where treatment options and efficacy are limited.

A number of risk-factors are associated with the biological establishment of pancreatic cancer including pre-malignant pancreatic cystic lesions.

Certain pancreatic cystic lesions possess the ability to undergo malignant transformation and are regarded as precursor lesions for pancreatic cancer.

Risk-stratification guidelines for the diagnosis and management of pancreatic cystic lesions remains highly contended within the field.

Incorporation of an immunobiological component to current risk-stratification guidelines of pancreatic cystic lesions may permit more accurate identification of at-risk patients for pancreatic cancer.

The prognosis for patients diagnosed with pancreatic cancer has changed little over the past 4 decades. Fewer than 20 % of patients are diagnosed at a stage amenable to potentially curative surgery and therapeutic resistance remains widespread, compounded by a lack of therapeutic targets. Early detection of pancreatic cancer is notoriously difficult, due to non-specific symptoms that delay early diagnosis in addition to limited sensitivity of current imaging modalities. However, pancreatic cystic lesions (PCLs), such as intraductal papillary mucinous neoplasms (IPMNs), provide a unique opportunity for earlier disease intervention. Indeed, PCLs can be stratified by risk of malignant transformation, but current stratification guidelines remain highly contended within the field. Importantly, accumulating evidence suggests that inflammatory and immunogenetic mechanisms may influence both cyst development and malignant progression, yet these immunobiological factors are not currently integrated into PCL risk-stratification and management frameworks. In this review, we focus on the immunobiological dimension of PCLs, highlighting the interplay between chronic inflammation, immune dysregulation, and genetic alterations that may drive cystogenesis and malignant transformation. Furthermore, we assess the evidence to support integrating an immunobiological aspect to existing risk stratification guidelines to enhance identification of high-risk pre-malignant PCLs. Such integration may ultimately identify high-risk patients more accurately and inform surveillance and therapeutic intervention strategies to prevent late-stage pancreatic cancer.

Image, graphical abstract

## Linked entities

- **Diseases:** pancreatic cancer (MONDO:0005192)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, VHL (von Hippel-Lindau tumor suppressor) [NCBI Gene 7428] {aka HRCA1, RCA1, VHL1, pVHL}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, CXCL13 (C-X-C motif chemokine ligand 13) [NCBI Gene 10563] {aka ANGIE, ANGIE2, BCA-1, BCA1, BLC, BLR1L}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, PTGER2 (prostaglandin E receptor 2) [NCBI Gene 5732] {aka COX-2, EP2}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, RNF43 (ring finger protein 43) [NCBI Gene 54894] {aka RNF124, SSPCS, URCC}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, Mucin [NCBI Gene 100508689], IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, CXCL2 (C-X-C motif chemokine ligand 2) [NCBI Gene 2920] {aka CINC-2a, GRO2, GROb, MGSA-b, MIP-2a, MIP2}, CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}
- **Diseases:** fibrosis (MESH:D005355), metastasis (MESH:D009362), Barrett's oesophagus (MESH:D001471), PDAC (MESH:D021441), traumatic (MESH:D014947), Chronic inflammation (MESH:D007249), Benign pseudocysts (MESH:D010192), HG dysplasia (MESH:D015792), colon cancer (MESH:D015179), retention cysts (MESH:D016055), back pain (MESH:D001416), PC (MESH:D010190), gastroenteritis (MESH:D005759), Cystic lesions (MESH:D052177), tumorigenic (MESH:D002471), DM (MESH:D003920), gastrointestinal conditions (MESH:D005767), pancreatic cyst (MESH:D010181), VHL disease (MESH:D006623), PCs (MESH:C535424), PCL (MESH:D008209), carcinoma in situ (MESH:D002278), gallstones (MESH:D042882), lymphangiomas (MESH:D008202), carcinoma (MESH:D009369), cystic tumours (MESH:D018297), mucinous (MESH:D002288), eosinophilic oesophagitis (MESH:D000077277), CP (MESH:D050500), IPMN (MESH:D000077779), benign epithelial cysts (MESH:D002277), Acute pancreatitis (MESH:D010195), PanIN (MESH:D002578), atrophy (MESH:D001284), MDSC (OMIM:601308), serous cystadenomas (MESH:D018293), PCLs (MESH:D003550), weight loss (MESH:D015431), autosomal dominant (MESH:C566739), nausea (MESH:D009325), breast cancer (MESH:D001943), obesity (MESH:D009765), incidentalomas (MESH:C538238), loss of appetite (MESH:D001068), pneumonia (MESH:D011014), carcinogenesis (MESH:D063646), ovarian and cervical cancer (MESH:D010051), fatigue (MESH:D005221), jaundice (MESH:D007565), adenoma (MESH:D000236), necrosis (MESH:D009336), pancreatic disease (MESH:D010182), indigestion (MESH:D004415), chronic (MESH:D002908), IMPN cysts (MESH:D003560), BD (MESH:D001649), invasive carcinoma (MESH:D009361), squamous lined cysts (MESH:D002294)
- **Chemicals:** intra-cystic carcinoembryonic antigen (-), Prostaglandins (MESH:D011453), PGE2 (MESH:D015232), alcohol (MESH:D000438), reactive oxygen species (MESH:D017382), glucose (MESH:D005947)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** PC — Homo sapiens (Human), Pancreatic ductal adenocarcinoma, Cancer cell line (CVCL_1434)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12936487/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12936487/full.md

## References

175 references — full list in the complete paper: https://tomesphere.com/paper/PMC12936487/full.md

---
Source: https://tomesphere.com/paper/PMC12936487